32.34
0.03 (0.09%)
| Previous Close | 32.31 |
| Open | 32.29 |
| Volume | 213,816 |
| Avg. Volume (3M) | 390,358 |
| Market Cap | 1,629,518,848 |
| Price / Sales | 4.84 |
| Price / Book | 4.46 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -6.48% |
| Operating Margin (TTM) | -3.85% |
| Diluted EPS (TTM) | -0.430 |
| Quarterly Revenue Growth (YOY) | 33.20% |
| Quarterly Earnings Growth (YOY) | 864.20% |
| Total Debt/Equity (MRQ) | 114.67% |
| Current Ratio (MRQ) | 6.36 |
| Operating Cash Flow (TTM) | 31.08 M |
| Levered Free Cash Flow (TTM) | -21.36 M |
| Return on Assets (TTM) | -1.83% |
| Return on Equity (TTM) | -5.86% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Immunocore Holdings plc | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | -3.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 0.38 |
|
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 5.18% |
| % Held by Institutions | 97.28% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fiera Capital Corp | 30 Jun 2025 | 813,074 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BERMAN DAVID M | - | 35.86 | -73,151 | -2,639,728 |
| Aggregate Net Quantity | -73,151 | |||
| Aggregate Net Value ($) | -2,639,728 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 35.86 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BERMAN DAVID M | Officer | 15 Sep 2025 | Automatic sell (-) | 200 | 35.24 | 7,048 |
| BERMAN DAVID M | Officer | 15 Sep 2025 | Option execute | 200 | - | - |
| BERMAN DAVID M | Officer | 12 Sep 2025 | Automatic sell (-) | 22,532 | 35.24 | 794,028 |
| BERMAN DAVID M | Officer | 12 Sep 2025 | Option execute | 22,532 | - | - |
| BERMAN DAVID M | Officer | 11 Sep 2025 | Automatic sell (-) | 19,081 | 36.57 | 697,792 |
| BERMAN DAVID M | Officer | 11 Sep 2025 | Option execute | 19,081 | - | - |
| BERMAN DAVID M | Officer | 10 Sep 2025 | Automatic sell (-) | 31,338 | 36.41 | 1,140,860 |
| BERMAN DAVID M | Officer | 10 Sep 2025 | Option execute | 31,338 | - | - |
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Immunocore to present at upcoming investor conferences |
| 07 Aug 2025 | Announcement | Immunocore reports second quarter financial results and provides a business update |
| 31 Jul 2025 | Announcement | Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 |
| 30 Jun 2025 | Announcement | Er-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS Regions |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |